SIRIUS-biotech defined a contract with the National Institute for Cancer Research (IST), located in Genoa, for the commercialization of a large panel of murine monoclonal antibodies to human tenascin and fibronectin.
Name (required)
Mail (will not be published) (required)
Website
Higlights
Bone reconstruction evidence after tissue engineering study